Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | UNG | P13051 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542003 | 0.89 | PTPN1 (0.45) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL1506785 | 0.84 | MEN1 (0.47) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL28371598 | 0.84 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL9670483 | 0.81 | PTPN1 (0.62) | MEN1KMT2AALDH1A1HPGDPTPN1 | |
| SCHEMBL3272215 | 0.80 | ERN1 (0.50) | ALDH1A1HPGDKDM4EERN1TSHR | |
| SCHEMBL3268830 | 0.79 | KDM2B (0.45) | MEN1KMT2AERN1RAB9A | |
| SCHEMBL7537287 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| Benzoic Acid SCHEMBL27844693 | 0.79 | NPC1 (0.54) | MEN1KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL3388906 | 0.78 | PTGER4 (0.54) | MEN1KMT2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL7544129 | 0.78 | ERN1 (0.38) | MEN1KMT2AALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| EP-0802896-B1 | METHOD FOR PURIFYING CRUDE NAPHTHALENEDICARBOXYLIC ACID | MITSUI CHEMICALS INC (JP) | 2001-01-03 | — | — | EP | disclosed |
| US-5872284-A | CATALYTIC HYDROGENATION OF 2,6-NAPHTHALENEDICARBOXYLIC ACID COMPOUNDS IN WATER AND SOLVENT | MITSUI CHEMICALS, INC. (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0802896-A1 | METHOD FOR PURIFYING CRUDE NAPHTHALENEDICARBOXYLIC ACID | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-29 | — | — | EP | disclosed |
| WO-1997017318-A1 | METHOD FOR PURIFYING CRUDE NAPHTHALENEDICARBOXYLIC ACID | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-15 | — | — | WO | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | MEN1 1138/4885KMT2A 2352/4885ALDH1A1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.